The Science of Changing Lives
Agentix Biosciences (OTC:AGTX), is a clinical-stage biotechnology company that is pursuing the development of a comprehensive suite of novel, science-driven, biopharmaceuticals that target the endocannabinoid system across multiple therapeutic areas with greater market exclusivity, for the treatment of metabolic diseases; including Type 2 Diabetes Mellitus, Chronic Obesity, Non-alcoholic Fatty Liver Disease (NAFLD), and Non-alcoholic Steatohepatitis (NASH). AGENTIX acquired specific assets and licensing rights, including licensing rights associated with intellectual property as part of Worldwide Exclusive Agreements with NHRI (National Heath Research Institute) and RTI (Research Triangle Institute) International.
Established Pharmaceuticals:
- Leveraging Molecules Already Approved as Drugs
- Applying Formulation and Drug Delivery Technologies to Provide Better Dosing
Innovative Pharmaceuticals
- Peripherally-Restricted Proprietary Molecules Which Act on the Peripheral Endocannabinoid Receptors; CB1 & CB2
- High Reward Prospects
- Offers a Period of Market Exclusivity
- Lower Clinical Risk Strategy
AGENTIX OFFERS A HIGH-CALIBRE SCIENTIFIC & RESEARCH TEAM
Products
Prioritizing our product pipeline to focus on greatest scientific and commercial value: immunology, oncology, neurology, pain and disorders.
Research & Development
Utilization of industry preclinical research and patient use accounts to drive next generation studies for alternative and pharmaceutical markets.
Leadership Team
Industry leaders are the forefront of Agentix Biosciences research and implementation approach to business that brings technology and solutions to market.
A Product Pipeline for Breakthrough Medicines
GSL Healthcare Inc., the company’s pharmaceutical division, has completed two significant transactions providing the company with a suite of commercialized products as well as a pipeline of therapeutic applications
GSL Healthcare acquired Applied BioPharma, LLC and its assets and has merged with Agentix Corp., a publicly listed company trading on the OTC in the United States.
Agentix has identified a targeted collection of Consumer Wellness and Pharmaceutical product opportunities, the majority of which will be designed to offer a more sophisticated and intelligent product offering in the multi-billion-dollar global Cannabinoid market. The first category shall consist of a series of health and wellness products that incorporate a proprietary and proven cellular delivery technology for the Consumer market. Further advancements of these novel biocomplexes will be used in the development and production of pharma-grade products for more specific clinical (non-prescription) applications, e.g. Arthritic Joint Pain and Onychomycosis.
AGENTIX BIOSCIENCES
The Science of Changing Lives
Agentix Biosciences (OTC:AGTX), is a clinical-stage biotechnology company that is pursuing the development of a comprehensive suite of novel, science-driven, biopharmaceuticals that target the endocannabinoid system across multiple therapeutic areas with greater market exclusivity, for the treatment of metabolic diseases; including Type 2 Diabetes Mellitus, Chronic Obesity, Non-alcoholic Fatty Liver Disease (NAFLD), and Non-alcoholic Steatohepatitis (NASH). AGENTIX acquired specific assets and licensing rights, including licensing rights associated with intellectual property as part of Worldwide Exclusive Agreements with NHRI (National Heath Research Institute) and RTI (Research Triangle Institute) International.
Established Pharmaceuticals:
- Leveraging Molecules Already Approved as Drugs
- Applying Formulation and Drug Delivery Technologies to Provide Better Dosing
Innovative Pharmaceuticals
- Peripherally-Restricted Proprietary Molecules Which Act on the Peripheral Endocannabinoid Receptors; CB1 & CB2
- High Reward Prospects
- Offers a Period of Market Exclusivity
- Lower Clinical Risk Strategy
AGENTIX OFFERS A HIGH-CALIBRE SCIENTIFIC & RESEARCH TEAM
Products
Prioritizing our product pipeline to focus on greatest scientific and commercial value: immunology, oncology, neurology, pain and disorders.
Research & Development
Utilization of industry preclinical research and patient use accounts to drive next generation studies for alternative and pharmaceutical markets.
Leadership Team
Industry leaders are the forefront of Agentix Biosciences research and implementation approach to business that brings technology and solutions to market.
A Product Pipeline for Breakthrough Medicines
GSL Healthcare Inc., the company’s pharmaceutical division, has completed two significant transactions providing the company with a suite of commercialized products as well as a pipeline of therapeutic applications
GSL Healthcare acquired Applied BioPharma, LLC and its assets and has merged with Agentix Corp., a publicly listed company trading on the OTC in the United States.
Agentix has identified a targeted collection of Consumer Wellness and Pharmaceutical product opportunities, the majority of which will be designed to offer a more sophisticated and intelligent product offering in the multi-billion-dollar global Cannabinoid market. The first category shall consist of a series of health and wellness products that incorporate a proprietary and proven cellular delivery technology for the Consumer market. Further advancements of these novel biocomplexes will be used in the development and production of pharma-grade products for more specific clinical (non-prescription) applications, e.g. Arthritic Joint Pain and Onychomycosis.